Guardant Health, Inc. (Form: S-8, Received: 02/23/2024 16:11:26)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

As filed with the Securities and Exchange Commission on February 23, 2024

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Guardant Health, Inc.

(Exact name of Registrant as specified in its charter)


Delaware		45-4139254
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

3100 Hanover Street Palo Alto, California		94304
(Address of Principal Executive Offices)		(Zip Code)

2018 Incentive Award Plan

2018 Employee Stock Purchase Plan

(Full Title of the Plan)

John Saia

Chief Legal Officer and Corporate Secretary

3100 Hanover Street

Palo Alto, California, 94304

(855) 698-8887

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Andrew Thorpe, Esq.

Elena Vespoli, Esq.

Gunderson Dettmer Stough Villeneuve

Franklin & Hachigian, LLP

One Bush Plaza

Suite 1200

San Francisco, California 94104

Tel: (415) 978-9803

Fax: (415) 978-9806

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an aggregate of an additional 4,795,700 shares of common stock of the Registrant issuable under the following employee benefit plans for which registration statements (File Nos. 333-227762, 333-236807, 333-253733, 333-263105 and 333-270241) of the Registrant on Form S-8 (the “Registration Statements”) are effective: (i) the Guardant Health, Inc. 2018 Incentive Award Plan which, as a result of the operation of an automatic annual increase provision therein, added 3,689,000 shares of common stock and (ii) the Guardant Health, Inc. 2018 Employee Stock Purchase Plan which, as a result of the operation of an automatic annual increase provision therein, added 1,106,700 shares of common stock.

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON

FORM S-8

Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on October 10, 2018 (File No. 333-227762), March 2, 2020 (File No. 333-236807), March 1, 2021 (File No. 333-253733), February 28, 2022 (File No. 333-263105) and March 2, 2023 (File No. 333-270241) are incorporated by reference herein.

EXHIBIT INDEX


Exhibit Number		Incorporated by Reference				Filed Herewith
Exhibit Number	Exhibit Description	Form	Date	Exhibit	File Number	Filed Herewith

4.1	Amended and Restated Certificate of Incorporation.	8-K	10-9-18	3.1	001-38683

4.2	Amended and Restated Bylaws.	8-K	10-9-18	3.2	001-38683

5.1	Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.					X

10.1	2018 Incentive Award Plan.	S-8	10-10-18	99.2(a)	333-227762

10.2	Form of Stock Option Agreement under the 2018 Incentive Award Plan.	S-1/A	9-21-18	10.9(a)	333-227206

10.3	Form of Restricted Stock Award Agreement under the 2018 Incentive Award Plan.	S-1/A	9-21-18	10.9(b)	333-227206

10.4	Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.	S-1/A	9-21-18	10.9(c)	333-227206

10.5	Forms of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.	10-K	2-25-21	10.3(d)	001-38683

10.6	2018 Employee Stock Purchase Plan.	S-8	10-10-18	99.3	333-227762

10.7	First Amendment to 2018 Employee Stock Purchase Plan.	10-K	3-29-19	10.4(a)	001-38683

23.1	Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.					X

23.2	Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.					X

23.3	Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).					X

24.1	Power of Attorney (incorporated by reference to the signature page hereto).					X

107	Filing Fee Table.					X

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, California, on February 23, 2024.


Guardant Health, Inc.

By:		/s/ Michael Bell
		Michael Bell
		Chief Financial Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Helmy Eltoukhy, AmirAli Talasaz and Michael Bell and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.


Signature	Title	Date

/s/ Helmy Eltoukhy Helmy Eltoukhy	Co-Chief Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors	February 23, 2024

/s/ AmirAli Talasaz AmirAli Talasaz	Co-Chief Executive Officer (Principal Executive Officer) and Director	February 23, 2024

/s/ Michael Bell Michael Bell	Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)	February 23, 2024

/s/ Ian Clark Ian Clark	Director	February 23, 2024

/s/ Vijaya Gadde Vijaya Gadde	Director	February 23, 2024

/s/ Meghan Joyce Meghan Joyce	Director	February 23, 2024

/s/ Steve Krognes Steve Krognes	Director	February 23, 2024


/s/ Myrtle Potter Myrtle Potter	Director	February 23, 2024

/s/ Musa Tariq Musa Tariq	Director	February 23, 2024

Exhibit 5.1

LOGO

February 23, 2024

Guardant Health, Inc.

3100 Hanover Street

Palo Alto, CA 94304

Ladies and Gentlemen:

We refer to the registration statement on Form S-8 (the “Registration Statement”) to be filed by Guardant Health, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “Commission”) in connection with the registration under the Securities Act of 1933, as amended (the “Act”), of an aggregate of 4,795,700 shares of the Company’s common stock, par value $0.00001 per share (the “Shares”), that are subject to issuance by the Company (i) upon the exercise or settlement of awards granted or to be granted under the Company’s 2018 Incentive Award Plan and (ii) upon the exercise of purchase rights to acquire Shares under the Company’s 2018 Employee Stock Purchase Plan. The Company’s 2018 Incentive Award Plan and the Company’s 2018 Employee Stock Purchase Plan are collectively referred to in this letter as the “Plans.”

In connection with this opinion, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the Plans. We have also examined and relied upon the Registration Statement and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. With your consent, we have relied upon certificates and other assurances of officers of the Company as to factual matters without having independently verified such factual matters. We have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.

This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, other than as expressly stated herein with respect to the issue of the Shares. Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely with respect to the federal laws of the United States and the General Corporation Law of the State of Delaware. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof.

GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP

One Bush Plaza, Suite 1200 San Francisco, CA 94104 gunder.com

Based upon and subject to the foregoing, we advise you that, in our opinion, when the Shares have been issued pursuant to the applicable provisions of the Plans and pursuant to the agreements which accompany the Plans, and in accordance with the Registration Statement, such Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

GUNDERSON DETTMER STOUGH

VILLENEUVE FRANKLIN & HACHIGIAN, LLP

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 22, 2024, relating to the financial statements of Guardant Health, Inc. and the effectiveness of Guardant Health Inc.’s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Guardant Health, Inc. for the year ended December 31, 2023.

/s/ Deloitte & Touche LLP

San Jose, California

February 23, 2024

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2018 Incentive Award Plan and the 2018 Employee Stock Purchase Plan of Guardant Health, Inc. of our report dated February 23, 2023, with respect to the consolidated financial statements of Guardant Health, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California

February 22, 2024

Exhibit 107

Calculation of Filing Fee Tables

Form S-8

(Form Type)

Guardant Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type

Security

Class

Title

Fee
Calculation
Rule

Amount
Registered (1)

Proposed
Maximum
Offering
Price Per
Share

Maximum

Aggregate

Offering

Price

Fee

Rate

Amount of
Registration
Fee

Equity

Common Stock, $0.00001 par value per share

457(c)

and 457(h)

3,689,000(2)

$22.12(3)

$81,600,680.00

$147.60 per $1,000,000

$12,044.27

Equity

Common Stock, $0.00001 par value per share

457(c)

and 457(h)

1,106,700(4)

$18.80(5)

$20,805,960.00

$147.60 per $1,000,000

$3,070.96

Total Offering Amounts

$102,406,640.00

$15,115.23

Total Fees Previously Paid

—

Total Fee Offsets (6)

—

Net Fee Due

$15,115.23

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the common stock, $0.00001 par value per share (“Common Stock”) of Guardant Health, Inc. (the “Registrant”), that become issuable under the 2018 Incentive Award Plan (the “2018 Plan”) and the 2018 Employee Stock Purchase Plan (the “2018 ESPP”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of Common Stock.

(2)	Represents additional shares of the Registrant’s Common Stock that became available for issuance on January 1, 2024 under the 2018 Plan by operation of an automatic annual increase provision therein.

(3)

Estimated in accordance with Rules 457(c) and 457(h) under the Securities Act solely for the purpose of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based upon the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Select Market on February 16, 2024, which date is within five business days prior to filing this Registration Statement.

(4)	Represents additional shares of the Registrant’s Common Stock that became available for issuance on January 1, 2024 under the 2018 ESPP by operation of an automatic annual increase provision therein.

(5)

(6)	The Registrant does not have any fee offsets.